Please assess the completion status of the following clinical trial:

Trial Title: Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 to 50 years old.~2. Available for clinical follow-up through Week 48 after enrollment.~3. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.~4. Able and willing to provide fingerprints and have their photographs taken including injection site photographs.~5. Must allow home visits~6. Must complete an Assessment of Understanding (AoU) prior to enrollment by answering 9 out of 10 questions at least once in 3 attempts.~7. Able to read (English or Luganda) and willing to complete the informed consent process.~8. In good general health without clinically significant medical history.~9. Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) ≤ 40 within the 56 days prior to enrollment.~10. Laboratory Criteria within 56 days prior to enrollment:~    1. Hemoglobin ≥ 11.0 g/dL for women; ≥12.5 g/dL for men.~   2. White blood cells (WBC) = 2,500-12,000 cells/mm\^3.~   3. Total lymphocyte count ≥ 800 cells/mm\^3.~   4. Platelets = 125,000 - 400,000/mm\^3.~   5. Alanine aminotransferase (ALT) ≤ 1.25 x upper limit of normal.~   6. Serum creatinine ≤ 1 x upper limit of normal.~   7. HIV-uninfected as evidenced by a negative FDA-approved HIV diagnostic test.~    Female-Specific Criteria:~11. Negative β-HCG (human chorionic gonadotropin) pregnancy test; serum β-HCG at screening and urine β-HCG at enrollment if woman is of reproductive potential.~12. Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 24 weeks after study vaccination if assessed to be of reproductive potential.~Exclusion Criteria:~Volunteer has received any of the following substances:~1. Investigational Ebola or Marburg vaccine in a prior clinical trial or prior receipt of a cAd3 adenoviral vectored investigational vaccine.~2. Chronic use of immunomodulators and systemic glucocorticoids in daily doses of glucocorticoid equivalence \> 20 mg of prednisolone, for periods exceeding 10 days. Non-steroidal anti-inflammatory drugs \[NSAIDS\] are permitted. Participants that have used less than the stated glucocorticoid dose may still be excluded at the Investigator's discretion.~3. Blood products within 112 days (16 weeks) prior to enrollment.~4. Investigational research agents within 28 days (4 weeks) prior to enrollment.~5. Live attenuated vaccines within 28 days (4 weeks) prior to enrollment.~6. Subunit or killed vaccines within 14 days (2 weeks) prior to enrollment.~7. Current anti-tuberculosis prophylaxis or therapy.~   Female-specific criteria:~8. Woman who is pregnant, breast-feeding or planning to become pregnant during the first 24 weeks after study vaccine administration.~   Volunteer has a history of any of the following clinically significant conditions:~9. Serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain.~10. Allergic reaction to excipients in the study vaccine including gentamycin, neomycin or streptomycin.~11. Clinically significant autoimmune disease or immunodeficiency.~12. Asthma that is not well controlled.~13. Positive result on a rapid plasma reagin (RPR) test.~14. Diabetes mellitus (type I or II).~15. Thyroid disease that is not well controlled.~16. A history of hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema.~17. Idiopathic urticaria within the last 1 year.~18. Hypertension that is not well controlled.~19. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.~20. A malignancy that is active, currently being treated, or not surgically cured.~21. Seizure in the past 3 years or treatment for seizure disorder in the past 3 years.~22. Asplenia or functional asplenia.~23. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within five years prior to enrollment, history of a suicide plan or attempt.~24. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: cAd3-EBO S vaccine (1x10^10 PU) (Type: EXPERIMENTAL): cAd3-EBO S vaccine (1x10\^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
- Group 2: cAd3-EBO S vaccine (1x10^11 PU) (Type: EXPERIMENTAL): cAd3-EBO S vaccine (1x10\^11 PU) administered IM with needle and syringe in a volume of 1 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete